Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. - IIIBurris, Howard A; Flinn, Ian W; Patel, Manish R; Fenske, Timothy S; Deng, Changchun; Brander, Danielle M; Gutierrez, Martin; Essell, James H; Kuhn, John G; Miskin, Hari P; Sportelli, Peter; Weiss, Michael S; et al. (Lancet Oncology, 2018)